维普期刊资源整合服务平台（V6.5）

77篇 您的检索式：作者名="Rustin G"

选中清除导出查看参考文献查看引证文献引用追踪共4页首页上一页第1页下一页末页 /4 跳转

	题名	作者	年代	出处	被引量
1	What surveillance plan should be advised for patients in re- mission after completion of first-line therapy for advanced ovarian canc er显示文摘	Rustin G J	2010	Int J Gynecol Cancer2010，20，2：	1
2	A Phase Ib trial of CA4P (combretastatin A-4 phosphate),carboplatin,and paclitaxel in patients with advanced cancer显示文摘	Rustin G J Shreeves G Nathan P D	2010	Br J Cancer2010，102，9：	1
3	How to follow up patients with epithelial o- varian cancer显示文摘	Miller R E Rustin G J	2010	Curr ()pin Oncol2010，22，49：	1
4	Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels显示文摘	Rustin G J Marples M Nelstrop AE	2001	Clin Oncol2001，19，20：	1
5	Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer) 显示文摘	Rustin G J Quinn M Thigpen T	2004	J Natl Cancer Inst2004，96，6：	1
6	Use of neoadjuvant chemotherapy prior to radical hysterectomy in cervical cancer:monitoring tumour shrinkage and molecular profile on magnetic resonance and assessment of 3 year outcome显示文摘	DeSouza NM Soutter WP Rustin G	2004	Br J Cancer2004，90，：	1
7	Role of tumour markers in monitoring epithelial ovarian cancer 显示文摘	Meyer T Rustin G J	2000	Br J Cancer2000，82，9：	1
8	Use of tumor markers in monitoring the course of ovarian cancer显示文摘	Rustin G J S Nelstrop A E Bentzen S M	1999	Ann Oncol1999，10，1：	1
9	Use of neoadju-vant chemotherapy prior to radical hysterectomy in cervicalcancer:monitoring tumor shrinkage and molecular profile onmagnetic resonance and assessment of 3-year outcome显示文摘	DeSouza NM Soutter WP Rustin G	2004	Br J Cancer2004，90，12：	1
10	Use of neo- adjuvant chemotherapy prior to radical hysterectomy in cervical cancer: monitoring tumor shrinkage and molecular profile on mag- netic resonance and assessment of 3 - year outcome 显示文摘	DESOUZA N M SOUTTER W P RUSTIN G	2004	Br J Cancer2004，90，12：	1
11	Role of tumour markers in monitoring epithelial overian cancer显示文摘	Meyer T Rustin G J S	2000	Brit J Cancer2000，82，9：	1
12	Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetie results 显示文摘	Rustin G J Galbraith SM Anderson H	2003	J Clin Oneol2003，21，：	1
13	Recurrent ovarian cancer: when and how to treat 显示文摘	Hall M Rustin G	2011	Curt Oncol Rep2011，13，：	1
14	Biological variationand analytical imprecision of CA 125 in patients with ovariancancer显示文摘	Tuxen MK Soletormos G Rustin GJ	2000	Scand J Clin Lab Invest2000，60，：	1
15	Use neoadjuvant chemotherapy priortoradical hysterectomyin cervicalcancer: monitoring tumour shrink age and molecular pvofileon magnetic resonance and assessment of 3 year outcome显示文摘	De Souza NM Soutter WP Rustin G	2004	Br J Cancer2004，90，12：	1
16	Role of tumour markers in monitoring epithelial ovarian cancer显示文摘	Meyer T Rustin G J		0，，09：	1
17	New guidelines to evaluate the response to treatment in solid tumors显示文摘	Rustin G J Quinn M Thigpen T		0，，6：	1
18	Phase I clinical trial of weekly combretastatin A4 phosphate: clinical and pharmacokinetic results显示文摘	Rustin G J Galbraith S M Anderson H Stratford M Folkes L KoSena L	2003	J Clin Oncol2003，21，：	1
19	Management of asympto- matic patients on follow-up for ovarian cancer with rising CA125 concentrations 显示文摘	Goonewardene T I Hall M R Rustin G J	2007	Lancet 0ncol2007，8，9：	1
20	Mitochondrial transcription factor A is necessary for mtDNA maintenance and embryogenesis in mice显示文摘	Larsson N G Wang J Wilhelmsson H Oldfors A Rustin P Lewandoski M	1998	Nat Genet1998，18，：	1

返回顶部每页显示：

共4页首页上一页第1页下一页末页 /4 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示